Southeast Asia is quietly emerging as one of the most dynamic frontiers in RNA interference (RNAi) biotechnology, as governments, academic institutions, and pharmaceutical companies converge on a technology once confined to Western research labs
Key takeaways
- Southeast Asia’s RNAi technology market, valued at USD 80.20 million in 2024, is set to grow at a striking 16.25% CAGR through 2033, driven by rising government support and expanding pharmaceutical R&D investment across the region.
- Singapore dominates the regional landscape, cementing its position as Asia’s premier precision medicine hub through landmark collaborations with global pharma giants including Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk.
- siRNA leads all RNAi modalities as the most commercially mature technology, with breakthrough research, such as NUS Medicine’s lipid nanoparticle therapy for liver disease, underscoring its growing clinical and commercial relevance across Southeast Asia.
A new industry analysis covering the period through 2033 paints a striking picture of accelerating momentum, and the numbers are hard to ignore.
According to a comprehensive market report published by UnivDatos Market Insights, the Southeast Asia RNAi Technology Market was valued at approximately USD 80.20 million in 2024 and is projected to expand at a compound annual growth rate (CAGR) of roughly 16.25% through 2033. That trajectory, driven by a confluence of government policy, academic-industry collaboration, and surging demand for precision medicine, would place the region firmly on the global map for RNA-based therapeutics and research services.
What Is RNAi, and Why Does It Matter?
RNA interference is a gene-silencing mechanism that enables scientists to selectively suppress the activity of specific genes using short interfering molecules. In practical terms, it offers researchers a molecular scalpel: the ability to turn off disease-causing genes with extraordinary precision. Since its discovery earned a Nobel Prize in 2006, RNAi has moved steadily from the laboratory bench toward clinical application, finding use in drug discovery, rare disease treatment, oncology, and metabolic disorder research.
In Southeast Asia, the technology is gaining traction precisely because it shortens drug development timelines, reduces the cost of target validation, and integrates well with the outsourcing models increasingly favored by pharmaceutical companies seeking efficiency in a competitive global market.
siRNA Dominates the Market Landscape
Among the various RNAi modalities, which include short hairpin RNA (shRNA) and microRNA (miRNA), short interfering RNA, or siRNA, commands the largest share of the regional market. Its dominance reflects a straightforward reality: siRNA is the most clinically validated and commercially mature format, supported by established delivery systems and a proven track record in rare diseases, oncology, and metabolic conditions.
A noteworthy example of siRNA’s real-world potential emerged from Singapore in late 2025, when researchers at NUS Medicine announced a novel RNA-based therapy for metabolic dysfunction-associated steatohepatitis (MASH), a liver condition affecting approximately 25% of people globally and up to 40% of adults in Singapore. The team used lipid nanoparticles to deliver siRNA directly into liver cells, where it silenced a gene called SPTLC2 that drives the accumulation of ceramides, fat-like molecules linked to liver inflammation and fibrosis. The breakthrough illustrated exactly the kind of translational research driving long-term commercial demand for siRNA tools across the region.
Pharma and Biotech Companies Lead Adoption
On the end-user side, pharmaceutical and biotechnology companies represent the dominant segment. Their strategy is clear: use RNAi technology to de-risk drug targets before committing to expensive clinical investment, thereby improving development efficiency and pipeline diversity. Southeast Asia’s pharma companies are increasingly outsourcing RNAi-based discovery efforts, a trend that is catalyzing the growth of specialized service providers and contract development and manufacturing organizations (CDMOs) throughout the region.
A notable example of this dynamic came in April 2025, when GenScript Biotech Corporation, a global leader in biotechnology research services, announced a strategic partnership with NSG Bio, Singapore’s premier biotech incubator. Under the agreement, GenScript committed to offering preferential rates and expert technical guidance across its full range of biotech services to incubator residents, a direct investment in the kind of early-stage ecosystem that feeds long-term RNAi adoption.
Singapore: The Undisputed Regional Hub
If there is one country that defines Southeast Asia’s RNAi ambitions, it is Singapore. The city-state’s combination of world-class intellectual property protections, a proactive government, deep life-science infrastructure, and proximity to global pharmaceutical leaders has made it the region’s dominant commercialization hub for RNA technologies.
The most striking signal of Singapore’s position came in December 2025, when Precision Health Research, Singapore (PRECISE) announced a landmark collaboration with four global pharmaceutical giants, Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk, under Phase II of Singapore’s National Precision Medicine (NPM) programme. The initiative marked Singapore as the first country in Asia to establish a pre-competitive collaboration with leading pharmaceutical companies, effectively setting the blueprint for how precision medicine ecosystems should be built in the region.
Thermo Fisher Scientific’s parallel investment reinforced the picture. In December 2025, the company announced an expansion of its bioprocessing capabilities across Asia, including a broadening of its existing Bioprocess Design Center in Singapore, offering bench-to-pilot scale bioprocessing, expert-led training, and technical collaboration to help companies scale early-stage processes toward sustainable biomanufacturing.
Vietnam: The Fastest-Growing Market to Watch
While Singapore commands today’s market, the report identifies Vietnam as the country expected to record the highest growth rate over the forecast period. Vietnam’s emergence reflects a broader pattern: as the biotech ecosystems of Indonesia, Thailand, the Philippines, and Malaysia continue to mature, RNAi adoption is spreading beyond the region’s established innovation hubs into markets characterized by rapidly improving lab infrastructure, growing research talent pipelines, and expanding government commitment to life sciences.
The Competitive Landscape
The Southeast Asia RNAi technology space features a mix of global giants and regional specialists. Key players operating in the market include GenScript, Integrated DNA Technologies (a Danaher Corporation subsidiary), Thermo Fisher Scientific, Merck KGaA, QIAGEN, Revvity, ABT Biomedical Solutions, and Bio Basic Asia Pacific. Their growth strategies span partnerships, new product launches, geographic expansions, and licensing agreements.
One example: in August 2025, Hongene Biotech Corporation, a CDMO focused on nucleic acid therapeutics, secured a non-exclusive licensing agreement with UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and modified oligonucleotides for research use. The deal expanded access to innovative oligonucleotide technologies for both academic and biopharmaceutical researchers working on RNAi, antisense oligonucleotides, CRISPR guides, and related modalities.
Challenges Ahead
The road to full regional maturity is not without obstacles. The report identifies limited local RNAi manufacturing capacity, the high cost of advanced tools, a shortage of specialists trained in RNA technologies, and uneven regulatory frameworks across countries as the principal headwinds. Regulatory complexity for RNA-based therapeutics remains particularly challenging: each Southeast Asian market brings its own approval pathways, complicating the commercialization strategies of companies seeking regional scale.
Uneven adoption is perhaps the most structural challenge. While Singapore and, increasingly, Malaysia and Vietnam are building the institutional and industrial scaffolding for serious RNAi development, other markets in the region are earlier in that journey. Bridging that gap will require sustained policy commitment, cross-border talent development, and deeper integration between academic research and commercial application.
The Bigger Picture
What the Southeast Asia RNAi market ultimately represents is a test of whether the region can convert scientific ambition into durable biotechnology competitiveness. The ingredients are increasingly in place: government support is growing, global companies are expanding their regional footprint, and breakthrough research, from Singapore’s liver disease therapy to the continent-wide precision medicine collaborations, is generating the kind of proof points that attract further investment.
At a 16.25% annual growth rate, the sector is expanding nearly twice as fast as the broader global healthcare market. For investors, researchers, and policymakers with a view toward the next decade of biomedical innovation, Southeast Asia’s RNAi story has only just begun
